Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
about
The danger theory: 20 years laterHemophilia A: an ideal disease to correct in uteroSeparating lentiviral vector injection and induction of gene expression in time, does not prevent an immune response to rtTA in ratsInduction of immune tolerance to FIX by intramuscular AAV gene transfer is independent of the activation status of dendritic cells.Loss of transgene following ex vivo gene transfer is associated with a dominant Th2 response: implications for cutaneous gene therapy.Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer.RETRACTED: Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapyMinicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type IToll-like receptor 3 is a potent negative regulator of axonal growth in mammals.Gene therapy progress and prospects: gene therapy for the hemophilias.Targeting dendritic cells for priming cellular immune responses.Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?Tolerance induction by viral in vivo gene transferCellular and genetic therapies for haemophilia.Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene deliveryEvolving gene therapy approaches for osteosarcoma using viral vectors: reviewGene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.Transgene-specific host responses in cutaneous gene therapy: the role of cells expressing the transgene.In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia BWFH State-of-the-Art Session on Therapeutic Gene Transfer Buenos Aires, Argentina.Central role of mitochondria in drug-induced liver injury.Endothelial progenitor cell-based therapy for hemophilia A.New approaches to gene and cell therapy for hemophilia.Mesenchymal stem cell treatment for hemophilia: a review of current knowledge.Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models.Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependentRecombinant factor VIII expression in hematopoietic cells following lentiviral transduction.Sustained viral gene delivery through core-shell fibers.Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.Gene therapy for hemophilia? No.The impact of antigen expression in antigen-presenting cells on humoral immune responses against the transgene product.
P2860
Q21131221-C6374EA0-A044-4995-B8A3-A8968D59A2D5Q26852638-1EE47253-2ADB-4C99-88BC-CD009C56A450Q33550771-84930D05-F01C-4154-B23B-B2398F74DF2EQ33608746-17BA179B-8568-4CEB-AB31-0FB9AF41EFAFQ33882677-B1149F87-72F4-4670-94CC-10FEA795753DQ34516810-8CA8ACD8-A9EB-40F8-B1B4-7EC307E63D40Q34621544-FE1DD337-20E4-47AC-ABC3-8DBE683F2A42Q34621690-A3FB0E3F-844E-499D-A41F-FD946EAA2644Q35037100-06184B65-BC06-48AF-BC0E-151A73D378C7Q35140784-F76D2C31-B0F8-473A-A859-16D307C2C209Q35549421-69742F3B-343B-40BD-8025-3A9FC2C7249AQ36230845-7EE1FC30-22F3-4CAB-9BE1-A94ABD68ED82Q36320026-62EA2D63-F0B7-4218-BDF7-1D8F008C2D68Q36473038-5312AF65-C3E0-407C-90E4-82B490F382D2Q36616672-7F6FB01B-3220-4AEA-854B-678FE3DBBA5EQ36692759-0E45C6AB-307F-47F8-B27D-E69531044CC8Q36801646-57CDCAD6-78A0-46A7-87B3-D19486E97E04Q37341382-B3157F2D-8C86-4235-A4B1-EDE6680B3CE4Q37472002-FCF284E6-A07A-4004-A1F5-F1F95473AB4CQ37768868-FAC7829E-26F5-4DC1-B938-EA45BE04CCAEQ37926590-1DB60A09-073A-45CB-A521-08ED42F48921Q37982239-D17C2A18-0225-47D3-946F-4B3F58432248Q38543280-5CFACF49-7016-4D43-AE93-0BE99B555B20Q38543282-7232F8B2-FC9E-4F78-A273-040612B820BFQ38937408-5A9FAF39-0ADD-49C2-81B4-8015291E5B21Q39506153-CCE0C175-B257-4710-B95C-4C0F2B995802Q40632785-3F8DEA6E-1E9A-4227-A43B-5BCC6FD3B69EQ42561096-1F374F9A-4533-4DF5-8629-4C59A051B5B0Q44819846-7D3A8856-0866-428E-930D-39B5BF81E612Q45856587-E681FA80-978F-4ADA-9991-81F3B811CAEAQ45877164-AB6BE59F-2920-4CCA-9E41-D01F18F59985Q45888458-A692C048-1547-4FED-AC03-940A3D6BEE3F
P2860
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@ast
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@en
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@nl
type
label
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@ast
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@en
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@nl
prefLabel
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@ast
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@en
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@nl
P1433
P1476
Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.
@en
P2093
Brian D Brown
David Lillicrap
P304
P356
10.1182/BLOOD-2001-11-0067
P407
P577
2002-08-01T00:00:00Z